{"name":"Sin Gon Kim","slug":"sin-gon-kim","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ezetimibe or ezetimibe-statin combination therapy","genericName":"Ezetimibe or ezetimibe-statin combination therapy","slug":"ezetimibe-or-ezetimibe-statin-combination-therapy","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Ezetimibe or ezetimibe-statin combination therapy","genericName":"Ezetimibe or ezetimibe-statin combination therapy","slug":"ezetimibe-or-ezetimibe-statin-combination-therapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9sdUVQVGVDM3hHZFlsUW5qdUlLM05ydUVnYlVxbGQ1VDRxVXdjSGRpcVowS0NUQm9CRHJwOE96ZEZFYlNnWkExQ1UxTExDby1tMFo0QUlBSDIzMjV4Rzl1X2hDNjFKV0Robk1xRzdB0gFyQVVfeXFMTVg3cjZ4Sl9HaHVwOFk3cU9LN1dXLXE5TVI3MTNUTk9yeWlPRXBZWWZlSWppQjVLYThFQXdFZGxTWW1EZWFqelJKc25NMHc4eVlfZk1tUUpDM3BSZ0dyRkJDZnVZcTdVWVpuMEZqdjBiSTFn?oc=5","date":"2025-05-02","type":"pipeline","source":"koreabiomed.com","summary":"Lilly, Novo Nordisk seek insurance coverage in Korea for diabetes drugs Mounjaro and Ozempic - koreabiomed.com","headline":"Lilly, Novo Nordisk seek insurance coverage in Korea for diabetes drugs Mounjaro and Ozempic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1vSmVzYWZwcnNYc2RnR3JZS244X3hZUVZxNG9QT3dLVXV3Y3hYMWNJczlCTUtlMFpobHFGSXZLZGhTS2xSdEx3LUR4SG5vNDdjMl94czJ6VTQwN2I1TzdR?oc=5","date":"2018-11-13","type":"pipeline","source":"Nature","summary":"A novel adiposity index as an integrated predictor of cardiometabolic disease morbidity and mortality - Nature","headline":"A novel adiposity index as an integrated predictor of cardiometabolic disease morbidity and mortality","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}